Sclerostin Antibodies (Romosozumab)
Overview
Romosozumab is a humanized monoclonal antibody that binds and inhibits sclerostin, a glycoprotein produced by osteocytes that negatively regulates the Wnt signaling pathway. By blocking sclerostin, romosozumab increases Wnt pathway activity in osteoblasts, simultaneously promoting bone formation and reducing bone resorption.
Mechanism of Action
This dual mechanism produces rapid and substantial increases in bone mineral density. The antibody is composed of two heavy and two light immunoglobulin chains in a standard IgG2 configuration.
Research Summary & Key Findings
Romosozumab received FDA approval in 2019 based on the FRAME and ARCH trials, which demonstrated significant reductions in vertebral, clinical, and hip fractures in postmenopausal women with osteoporosis. The ARCH trial (NEJM, 2017) showed superior fracture reduction compared to alendronate over 24 months. A boxed warning was added regarding cardiovascular risk, including myocardial infarction and stroke, based on numerical imbalances observed in the ARCH study.
Clinical Status
Sclerostin Antibodies (Romosozumab) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Administration Routes
References
Primary literature
- PubMed — "Sclerostin Antibodies"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Sclerostin Antibodies"
Registered interventional and observational studies, including status and phase.
- PubChem — "Sclerostin Antibodies"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Bone
Teriparatide (Forteo)
FDA ApprovedA recombinant form of the first 34 amino acids of human parathyroid hormone (PTH 1-34). When administered intermittently...
View detailsAbaloparatide (Tymlos)
FDA ApprovedA synthetic 34-amino acid peptide analog of parathyroid hormone-related protein (PTHrP 1-34) that selectively activates ...
View detailsCalcitonin
FDA ApprovedA 32-amino acid peptide hormone naturally produced by parafollicular C-cells of the thyroid gland. Calcitonin inhibits o...
View detailsVosoritide (Voxzogo)
FDA ApprovedA C-type natriuretic peptide (CNP) analog that acts as an agonist at the natriuretic peptide receptor B (NPR-B) on growt...
View detailsStart Your Consultation
Get an AI-proposed Sclerostin Antibodies (Romosozumab) protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Sclerostin Antibodies (Romosozumab).
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.